IONIQ joins Cancer Early Detection Alliance
Salt Lake City, UT, September 8, 2022 – ProLung, Inc. dba IONIQ Sciences, Inc. (“IONIQ” or the “Company”) is proud to announce it has joined Cancer Early Detection Alliance (CEDA). CEDA’s mission to promote and expand access to quality, equitable care and early cancer detection aligns perfectly with IONIQ’s mission to modernize early-stage cancer detection. As an associate member, IONIQ joins a number of well-known patient advocacy groups and corporate members (e.g.: Lungevity, Prevent Cancer Foundation, Guardant Health and Freenome).
Mr. Jared Bauer, CEO, shared, “We are proud to join CEDA, as we share their vision about the importance of early-stage cancer detection. The clinical evidence continues continues to demonstrate that early detection saves lives and money. CEDA and IONIQ Sciences are focused on detection in the early-stages, when it matters most.”
About IONIQ Sciences, Inc.
IONIQ Sciences, Inc. is developing an advanced multi-cancer screening technology for early detection that has the potential to expand the therapeutic window, dramatically improve survivability and reduce the cost of healthcare. IONIQ Sciences operates at the confluence of its Electrical Impedance Analytics (EIA) or bioimpedance technology and Artificial Intelligence (AI). IONIQ Science’s first product utilizing its proprietary analytic platform, the IONIQ ProLung Test™ for lung cancer, has been designated a Breakthrough Device by the U.S. FDA.
About Cancer Early Detection Alliance (CEDA)
The Cancer Early Detection Alliance (CEDA) mission is to promote and expand access to quality, equitable care, and early cancer detection. CEDA seeks to advance meaningful policy opportunities geared towards early cancer detection. To lear more, please visit: www.cedalliance.org
IONIQ Sciences is proud to be a key supporter and member of the newly formed BioHive, a collective representing the life science and healthcare innovation ecosystem. By embracing diversity and collaboration, BioHive has become the fastest-growing life science community in America and their innovations are improving the lives of millions of patients. To learn more, please visit: www.biohive.com.
For further information about IONIQ Sciences, Inc., please contact:
Andy Robertson | 1-801-736-0729 | acr@IONIQsciences.com
IONIQ Sciences, Vice President of Business Development
IONIQ Sciences, Inc.
350 W. 800 N., Suite 214
Salt Lake City, Utah 84103